TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib

Grant

Date/time Interval

  • January 8, 2014 - January 7, 2019

    • Awarded By

    Total Award Amount

  • 38892.00

    • Direct Costs

  • 30867.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Investigator  
  • Lisle Nabell M.D.   Investigator